for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Idorsia Ltd

IDIA.S

Latest Trade

24.24CHF

Change

-0.34(-1.38%)

Volume

388,794

Today's Range

24.24

 - 

24.76

52 Week Range

15.20

 - 

28.00

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Latest Developments

Idorsia Says Janssen Reports Positive Top-Line Phase 3 Results For Ponesimod

July 26 (Reuters) - IDORSIA LTD <IDIA.S>::JANSSEN REPORTS POSITIVE TOP-LINE PHASE 3 RESULTS FOR PONESIMOD IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS.JANSSEN REPORTS POSITIVE TOP-LINE PHASE 3 RESULTS FOR PONESIMOD IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS.IDORSIA PHARMACEUTICALS LTD IS ENTITLED TO RECEIVE QUARTERLY PAYMENTS OF 8% OF NET SALES OF PONESIMOD PRODUCTS FROM ACTELION PHARMACEUTICALS LTD.STUDY MET ITS PRIMARY AND MOST SECONDARY ENDPOINTS.

Idorsia H1 US GAAP Net Loss At CHF 232 Mln

July 23 (Reuters) - IDORSIA LTD <IDIA.S>::UNCHANGED GUIDANCE FOR 2019: US GAAP OPERATING EXPENSES OF AROUND CHF 570 MILLION.UNCHANGED GUIDANCE: NON-GAAP OPERATING EXPENSES OF AROUND CHF 530 MILLION.US GAAP NET LOSS IN FIRST HALF OF 2019 AMOUNTED TO CHF 232 MILLION COMPARED TO CHF 159 MILLION FOR FIRST HALF OF 2018.US GAAP REVENUE OF CHF 13 MILLION IN FIRST HALF OF 2019 AS WELL AS 2018.US GAAP OPERATING EXPENSES IN FIRST HALF OF 2019 AMOUNTED TO CHF 252 MILLION (OF WHICH CHF 220 MILLION RESEARCH AND DEVELOPMENT AND CHF 33 MILLION SG&A EXPENSES).NON-GAAP NET LOSS IN FIRST HALF OF 2019 AMOUNTED TO CHF 222 MILLION.

Idorsia Q1 US GAAP Net Loss Widens To CHF 106 Mln

April 18 (Reuters) - Idorsia Ltd <IDIA.S>::IDORSIA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2019.US GAAP OPERATING EXPENSES IN Q1 2019 AT CHF 125 MILLION.NON-GAAP OPERATING EXPENSES IN Q1 2019 AT CHF 117 MILLION.UNCHANGED GUIDANCE FOR 2019.Q1 US GAAP NET LOSS AMOUNTED TO CHF 106 MILLION COMPARED TO CHF 79 MILLION.

Idorsia FY US GAAP Operating Expenses At CHF 432 Mln

Feb 7 (Reuters) - IDORSIA LTD <IDIA.S>::US GAAP OPERATING EXPENSES 2018 AT CHF 432 MILLION.NON-GAAP OPERATING EXPENSES 2018 AT CHF 399 MILLION, INCLUDING CHF 15.NON-GAAP OPERATING EXPENSES 2018 AT CHF 399 MILLION, INCLUDING CHF 15 MILLION MILESTONE PAYMENT TO REVERAGEN, IN LINE WITH 2018 GUIDANCE.SAYS GUIDANCE FOR 2019: US-GAAP OPERATING EXPENSES OF AROUND CHF 570 MILLION AND.SAYS FULL YEAR 2018, US GAAP NET LOSS AMOUNTED TO CHF 386 MILLION COMPARED TO CHF 14 MILLION FOR PERIOD ENDING DECEMBER 31, 2017..SAYS INCREASE OF NET LOSS WAS MAINLY DRIVEN BY LOWER REVENUES AND HIGHER OPERATING COSTS.AT END OF 2018, IDORSIA'S LIQUIDITY (INCLUDING CASH, CASH EQUIVALENTS, SHORT- AND LONG-TERM DEPOSITS) AMOUNTED TO CHF 1,220 MILLION..SAYS ALL LATE-STAGE TRIALS ARE NOW INITIATED, WITH DATA EXPECTED TO BE REPORTED IN 2020 AND 2021.SAYS MAKING 'GREAT PROGRESS' WITH EARLY-STAGE COMPOUNDS BY ACCUMULATING INFORMATION ON CLINICAL PHARMACOLOGY IN HEALTHY VOLUNTEERS OR CONDUCTING PHASE 2 PROFILING IN PATIENTS.SAYS CHF 505 MILLION RAISED IN JULY 2018 SHOULD GIVE IDORSIA NECESSARY LEEWAY TO ASSESS CLINICAL DATA FOR OUR LATE-STAGE PIPELINE AND THEN MAKE APPROPRIATE STRATEGIC DECISIONS REGARDING COMMERCIALIZATION.

Santhera Calls EGM And Proposes Ordinary Share Capital Increase

Nov 20 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG <SANN.S>::SANTHERA CALLS EXTRAORDINARY GENERAL MEETING AND PROPOSES ORDINARY SHARE CAPITAL INCREASE TO RAISE APPROXIMATELY CHF 50 MILLION.CAPITAL INCREASE TO BE EFFECTED BY WAY OF AN ACCELERATED BOOK BUILDING.CAPITAL INCREASE TO FINANCE INITIAL PAYMENT OF USD 20 MILLION TO IDORSIA FOR RIGHTS TO VAMOROLONE.CAPITAL INCREASE ALSO TO FINANCE DEVELOPMENT OF VAMOROLONE AND TO FUND ITS ONGOING ACTIVITIES.WILL ISSUE 1,000,000 NEW REGISTERED SHARES TO IDORSIA FROM ITS EXISTING AUTHORIZED CAPITAL.

Santhera Enters Into Agreement To Buy Option From Idorsia For Exclusive Sub-License Of First-In-Class Dissociative Steroid Vamorolon

Nov 20 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG <SANN.S>::SANTHERA ENTERS INTO AGREEMENT TO ACQUIRE OPTION FROM IDORSIA FOR EXCLUSIVE SUB-LICENSE OF FIRST-IN-CLASS DISSOCIATIVE STEROID VAMOROLON.IDORSIA TO BECOME LARGEST SHAREHOLDER IN SANTHERA WITH A 13.3% EQUITY STAKE.

Idorsia Maintains Collaboration Agreement With Reveragen

Nov 5 (Reuters) - Idorsia Ltd <IDIA.S>::MAINTAINS COLLABORATION AGREEMENT WITH REVERAGEN.FOLLOWING RECEIPT OF CLINICAL STUDY REPORT FOR PHASE 2A STUDY WITH VAMOROLONE, WILL PAY REVERAGEN USD 15 MILLION TO MAINTAIN AGREEMENT.

Idorsia Says Representative Of Former Axovan Shareholders Filed Complaint Against Actelion

Oct 24 (Reuters) - IDORSIA LTD <IDIA.S>::SAYS REPRESENTATIVE OF FORMER AXOVAN SHAREHOLDERS CLAIMS DEMERGER OF ACTELION AND IDORSIA WOULD TRIGGER ACCELERATION OF ALL OUTSTANDING MILESTONE PAYMENTS FOR CLAZOSENTAN.SAYS REPRESENTATIVE OF FORMER AXOVAN SHAREHOLDERS HAS FILED A COMPLAINT AGAINST ACTELION.BELIEVES THAT SUCH CLAIM HAS NO MERIT.

Idorsia 9Mth US GAAP Net Loss Of CHF 278 Mln

Oct 23 (Reuters) - IDORSIA LTD <IDIA.S>::US GAAP OPERATING RESULTS IN 9M 2018: LOSS OF CHF 271 MILLION.NON-GAAP* OPERATING RESULTS 9M 2018: LOSS OF CHF 247 MILLION.UNCHANGED GUIDANCE FOR 2018: NON-GAAP OPERATING EXPENSES OF AROUND CHF 390 MILLION.9MTH US GAAP NET LOSS AMOUNTED TO CHF 278 MILLION.

Idorsia H1 US GAAP Net Loss At CHF 159 Mln

July 24 (Reuters) - IDORSIA LTD <IDIA.S>::US GAAP OPERATING RESULTS IN HY 2018: LOSS OF CHF 155 MILLION.NON-GAAP* OPERATING RESULTS HY 2018: LOSS OF CHF 139 MILLION.UNCHANGED GUIDANCE FOR 2018: NON-GAAP OPERATING EXPENSES OF AROUND CHF 390 MILLION.H1 US GAAP NET LOSS AMOUNTED TO CHF 159 MILLION RESULTING IN A NET LOSS PER SHARE OF CHF 1.34.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up